Evidence map›Paper›PMID 42204862›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2026

Recommendations for genetic counseling for individuals at risk of autosomal dominant Alzheimer's disease in Latin America.

Daniel A Jiménez, Pablo M Bagnati, Rosa Elena Flores-Montes, María Laura Fernández, Angélica Zuno-Reyes, David Aguillon, Carmen Alaez-Verson, Luis E Becerra-Solano, María Isabel Behrens, Kelly Branda and 17 more

Abstract read
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Daniel A JiménezTranslational Neurology and Neurophysiology Lab, CICA Oriente, Department of Neurological Sciences, Faculty of Medicine, University of Chile, Santiago, Chile.ORCID https://orcid.org/0000-0001-8282-2945
Pablo M BagnatiDepartment of Cognitive Neurology, Neuropsychiatry and Neuropsychology, Fleni Neurological Research Institute, Buenos Aires, Argentina.
Rosa Elena Flores-MontesCínica de Neuropsiquiatría y Demencias. Servicio de Psiquiatría del Hospital Civil de Guadalajara Fray Antonio Alcalde., Jalisco, Mexico.
María Laura FernándezDepartment of Cognitive Neurology, Neuropsychiatry and Neuropsychology, Fleni Neurological Research Institute, Buenos Aires, Argentina.
Angélica Zuno-ReyesInstituto de Neurociencias CUCBA, Universidad de Guadalajara, Jalisco, Mexico.
David AguillonGrupo de Neurociencias de Antioquia, Facultad de Medicina, Universidad de Antioquia, Medellín, Colombia.
Carmen Alaez-VersonLaboratorio de Diagnóstico Genómico, Instituto Nacional de Medicina Genómica (INMEGEN), Mexico city, Mexico.
Luis E Becerra-SolanoDepartamento de clínicas, CUAltos, Universidad de Guadalajara, Tepatitlán, Jalisco, Mexico.
María Isabel BehrensCentro de Investigación Clínica Avanzada (CICA-HCUCH), Hospital Clínico Universidad de Chile, Santiago, Chile.
Kelly BrandaInformedDNA, St Petersburg, Florida, USA.
Patricio ChremDepartment of Cognitive Neurology, Neuropsychiatry and Neuropsychology, Fleni Neurological Research Institute, Buenos Aires, Argentina.
Nilton CustodioInstituto Peruano de Neurociencias, Unidad de diagnóstico de deterioro cognitivo y prevención de demencia, Lima, Peru.
Whitney DucaineInformedDNA, St Petersburg, Florida, USA.
Sofia Dumois-PetersenLaboratorio de Ciencias Clínicas CuValles, Universidad de Guadalajara, Jalisco, Mexico.
Luis FigueraDivisión de Genética, CIBO-IMSS & Doctorado en Genética Humana CUCS-Universidad de Guadalajara, Jalisco, Mexico.
Marisol Londoño CastañoFacultad de Teología, Filosofía y Humanidades, Universidad Pontificia Bolivariana, Medellín, Colombia.
Erika Mariana LongoriaCognitive Neurosciences Lab, National Institute of Neurology and Neurosurgery, Mexico City, Mexico.
Esmeralda MatuteInstituto de Neurociencias CUCBA, Universidad de Guadalajara, Jalisco, Mexico.
Victor SánchezDepartamento de clínicas, CUAltos, Universidad de Guadalajara, Tepatitlán, Jalisco, Mexico.
Andrea SlachevskyUnidad de Memoria - Centro de Memoria y Neuropsiquiatría (CMYN), Servicio de Neurología, Hospital del Salvador y Facultad de Medicina, Universidad de Chile, Santiago, Chile.
Ana Luisa SosaLaboratorio de Demencias del Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez, Mexico City, Mexico.
Ezequiel SuraceLaboratorio de Enfermedades Neurodegenerativas, Instituto de Neurociencias (INEU, CONICET-Fleni), Buenos Aires, Argentina.
Leonel TakadaCognitive and Behavioral Unit, Hospital das Clinicas, Department of Neurology, University of São Paulo Medical School, São Paulo, Brazil.
Lauren YaegerBernard Becker Medical Library, Washington University in St. Louis, Missouri, USA.
Ellen ZiegemeierDepartment of Neurology, Washington University School of Medicine, St Louis, Missouri, USA.
Jorge J Llibre GuerraDepartment of Neurology, Washington University School of Medicine, St Louis, Missouri, USA.
Programa de asesoramiento genético en América Latina (PRAGA)

Funding

Understanding Alzheimer disease heterogeneity in Hispanic populations.K01AG073526 · NIA · WASHINGTON UNIVERSITY · PI Jorge Jesus Llibre-Guerra · 2022 to 2026
$511k
Alzheimer's Association SG-20-690363ANID/FONDECYT 11231023Foundation for Barnes-Jewish HospitalMcDonnell International Scholars Academy, Washington University in St. LouisNIA NIH HHS K01 AG073526NIA NIH HHS K01AG073526
6 · The paper itself

Abstract

Autosomal dominant Alzheimer's disease (ADAD) represents a small but impactful subset of Alzheimer's cases. Asymptomatic individuals at genetic risk face substantial personal and family implications when considering predictive testing for known familial variants. Genetic counseling and testing (GCT) frameworks remain limited in Latin America (LatAm). Recommendations for GCT in LatAm were developed through an iterative, multidisciplinary consensus process. Evidence inputs included a structured literature review, site-level recommendations from participating LatAm centers, and a qualitative synthesis of focus groups with experienced investigators. The resulting model includes pre-test evaluation, sample collection, result disclosure, and structured follow-up. Core elements comprise mental health assessment, psychoeducation, exploration of expectations and decision-making needs, guided disclosure with emotional support, and a suggested 3-month post-disclosure reassessment using validated psychological measures. Our framework provides structured guidance for the safe and ethical delivery of GCT for ADAD through a multidisciplinary, culturally informed, and patient-centered approach in LatAm.

Indexed as

Alzheimer DiseaseGenetic CounselingGenetic Predisposition to DiseaseGenetic TestingHumansLatin Americaautosomal dominant Alzheimer's diseasecultural adaptationgenetic counselingLatin Americapsychological impact

Identifiers

PMID42204862
PMCPMC13240099

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.